A Phase 1 Clinical Study of SKB315 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate
the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB315 for
injection in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.